CHIRP02 - Immune Reponses to RSV B Challenge in Older Adults

Open-label trial of respiratory syncytial virus B in respiratory syncytial virus infection (RSV) (2 arms), sponsored by Imperial College London. Primary endpoints: Number, frequency and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) at 28 days, Number, frequency and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) relating to the bronchoscopy sampling at 28 days and 3 more. Planned start Aug 2026; status: not yet recruiting.